'We will have multiple engine options -- electric vehicle and internal combustion engine in diesel and petrol.'
The Softbank-backed company has set a price band of Rs 72 to Rs 76 per share for the maiden share sale and is expected to test the appetite for new-age loss-making companies.
Dengue has become a major public health concern in India with 289,235 cases reported last year. This year there were 19,447 cases of dengue which resulted in 19 deaths till April 2024.
New Delhi-based pharmaceutical major Mankind Pharma is poised to take pole position in women's health portfolio in the India Pharma Market (IPM) after completing the Rs 13,630 crore deal to acquire Bharat Serums and Vaccines (BSV), senior company officials said. The deal potentially opens doors for Mankind Pharma to the overseas markets, which currently draws 92 per cent of its revenues from India. The combined entity will draw around 13 per cent revenues from the international market, with the remaining coming from the domestic market.
'Bilateral trade has suffered seriously because of the growing unrest.' 'There is a standstill on both sides amid the curfew.'
The scare of communicable diseases seems to be gripping the country with Maharashtra reporting 28 Zika cases this year, the highest since 2021.
Kerala has had 202 fatalities in 2024 so far. In July alone, there were 202,122 episodes of fever, 2,250 cases of dengue, 1,850 cases of mumps and several other illnesses. 10,000 cases of dengue have been reported from Karnataka. 1,000 swine flu cases have been documented in Rajasthan.
The battle for the top spot in the two-wheeler market is intensifying. The gap between Hero MotoCorp and Honda Motorcycle & Scooter India (HMSI) in retail sales narrowed to just 45,607 units in June. This improvement comes as HMSI has clawed back market share after dipping to a historic low of 18 per cent in May 2023. Now, the retail market shares of the two companies are 28.86 per cent and 25.54 per cent, respectively, compared to 35.54 per cent and 18.05 per cent in May 2023.
Study suggested that constant use of Semaglutide may be linked to development of a condition called non-arteritic ischemic optic neuropathy.
Most of the pharma units are failing in documentation, and validation processes, and many don't have full-fledged quality control laboratories.
After reports claimed that filings in patent offices in India, the US, and Europe did not mention ICMR or its scientists, but only BBIL and its scientists, the Hyderabad-based biotechnology (biotech) company clarified that in the "rush" to develop vaccines and file appropriate patents, BBIL had missed adding ICMR's name in the original filings.
Auto manufacturers have focused on launching CNG variants of their popular models to meet consumer demand for vehicles with lower running costs.
'There is not any negative connotation associated with it.'
'That is a significant milestone for us and something we aspired for.'
India currently does not have any XBB 1.5 variant-based vaccines available.
Several firms are stepping up to help their workforce cope with soaring temperatures
India has covered enough population with vaccine and infection, but protein vaccines should remain available on payment basis for elderly and those with comorbidities.
Automotive (auto) major Mahindra & Mahindra (M&M), which is readying to launch nine sport utility vehicles (internal combustion engine/ICE), seven Born Electric Vehicles (BEVs), and seven light commercial vehicles by 2030, has outlined an investment of Rs 27,000 crore in its auto business between 2024-25 (FY25) and 2026-27 (FY27). Over the next three years, the company will deploy Rs 37,000 crore, including its auto business, farm business (Rs 5,000 crore), and service business (Rs 5,000 crore).
Maintaining the balance of gut microbiota is important as an imbalance, also known as dysbiosis, can cause or aggravate different diseases, including but not limited to digestive problems such as inflammatory bowel syndrome, mental health issues like anxiety and depression and menstrual problems.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances